SEC ends Waldencast (NASDAQ: WALD) investigation with no enforcement action
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Waldencast plc reported that staff of the U.S. Securities and Exchange Commission have concluded their investigation into the company’s restatement of financial results and material weaknesses in internal control over financial reporting related to historical accounting practices at Obagi Cosmeceuticals.
Based on the information available as of the notice date, the SEC staff indicated they do not intend to recommend an enforcement action against Waldencast. The company notes it voluntarily contacted the SEC about these matters, fully cooperated throughout the investigation, and incurred substantial legal, advisory and related costs while continuing to focus on governance, internal controls and executing its business plans.
Positive
- SEC investigation concluded with no enforcement recommendation: SEC staff notified Waldencast that, based on information available as of the notice date, they do not intend to recommend an enforcement action following the probe into restated results and internal control weaknesses.
Negative
- None.
Insights
SEC staff ended Waldencast’s investigation without intending enforcement action, easing a key regulatory overhang.
The staff of the SEC concluded their investigation into Waldencast’s restatement and internal control weaknesses tied to Obagi Cosmeceuticals’ historical accounting practices and, based on current information, do not intend to recommend an enforcement action. This removes the immediate risk of regulatory penalties from this matter.
The company previously disclosed the investigation, voluntarily contacted the SEC and fully cooperated, incurring substantial legal and advisory costs. With the investigation concluded, future disclosures may focus more on business performance and ongoing governance and control improvements rather than legacy accounting issues.
Key Figures
Investigation conclusion date: April 28, 2026
Obagi Medical experience: over 35 years
Milk Makeup founding year: 2016
3 metrics
Investigation conclusion date
April 28, 2026
Date Waldencast announced SEC staff had concluded the investigation
Obagi Medical experience
over 35 years
Legacy of Obagi Medical’s advanced skin care line
Milk Makeup founding year
2016
Year Milk Makeup, a Waldencast brand, was founded
Key Terms
restatement of its financial results, material weaknesses in its internal control over financial reporting, enforcement action, foreign private issuer, +1 more
5 terms
restatement of its financial results financial
"investigation of the Company relating to Waldencast’s restatement of its financial results and material weaknesses"
material weaknesses in its internal control over financial reporting financial
"material weaknesses in its internal control over financial reporting related to historical accounting practices"
enforcement action regulatory
"the SEC does not intend to recommend an enforcement action against Waldencast"
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
internal controls financial
"upholding strong governance, and ensuring robust internal controls"
Internal controls are the policies, procedures and routine checks a company uses to keep its financial records accurate, safeguard assets, and ensure laws and internal rules are followed. For investors they matter because strong controls reduce the risk of accounting errors, fraud or surprise liabilities; think of them as locks, alarms and bookkeeping checklists that make a company’s reported results more trustworthy and lower the chance of unexpected losses.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: April 2026
Commission File Number: 001-40207
Waldencast plc
(Translation of Registrant’s name into English)
81 Fulham Road
London, SW3 6RD
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Press Release
On April 28, 2026, Waldencast plc issued a press release, a copy of which is attached hereto as Exhibit 99.1 to this Form 6-K.
The information in this report on Form 6-K (including Exhibit 99.1 hereto) (the “Report”) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
EXHIBIT INDEX
| EXHIBIT NO. | DESCRIPTION | |||||||
| 99.1 | Press release of Waldencast plc, dated April 28, 2026 | |||||||
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Waldencast plc | |||||||||||
(Registrant) | |||||||||||
Date: April 28, 2026 | By: | /s/ Michel Brousset | |||||||||
Name: | Michel Brousset | ||||||||||
Title: | Chief Executive Officer | ||||||||||
3
Exhibit 99.1
Waldencast announces conclusion of SEC investigation
April 28, 2026
LONDON, April 28, 2026 (GLOBE NEWSWIRE) – Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the “SEC”) that they have concluded their investigation of the Company relating to Waldencast’s restatement of its financial results and material weaknesses in its internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals (the “Investigation”) and, based on the information available as of the date of the notice, the SEC does not intend to recommend an enforcement action against Waldencast.
“We are pleased with the favorable outcome of the SEC’s investigation.” stated Michel Brousset, Chief Executive Officer of Waldencast. “Throughout the Investigation, we fully cooperated and dedicated significant resources to the process. At the same time, we maintained our focus on executing our business plans, upholding strong governance, and ensuring robust internal controls.”
The Investigation was previously disclosed by the Company in its periodic reports under the Securities Exchange Act of 1934, as amended. As previously disclosed, the Company voluntarily contacted the SEC regarding these matters and has fully cooperated with the SEC throughout the course of the Investigation, incurring substantial legal, advisory and other related costs.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Obagi Medical is an industry-leading, advanced skin care line rooted in research and skin biology, refined with a legacy of over 35 years’ experience. Obagi Medical products are designed to address the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. More information about Obagi Medical is available on the brand’s website at www.obagi.com.
Founded in 2016, Milk Makeup quickly became a cult-favorite among the beauty community for its values of self-expression and inclusion, captured by its signature “Live Your Look”, its innovative formulas, and clean ingredients. The brand creates vegan, cruelty-free, clean formulas and has its Milk Makeup HQ in Downtown NYC. More information about Milk Makeup is available on the brand’s website at www.milkmakeup.com.
Contacts:
Investors
ICR
Allison Malkin
waldencastir@icrinc.com
ICR
Allison Malkin
waldencastir@icrinc.com
Media
ICR
ICR
Brittney Fraser/Alecia Pulman
waldencast@icrinc.com
FAQ
What did the SEC conclude about Waldencast (WALD) in its investigation?
The SEC staff concluded their investigation into Waldencast and, based on information available as of the notice date, stated they do not intend to recommend an enforcement action. The probe focused on restated results and internal control weaknesses tied to Obagi Cosmeceuticals’ historical accounting practices.
What issues were examined in the SEC investigation of Waldencast (WALD)?
The investigation covered Waldencast’s restatement of financial results and material weaknesses in internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals. These matters had been previously disclosed in Waldencast’s periodic reports under the Securities Exchange Act of 1934.
Did Waldencast (WALD) cooperate with the SEC during the investigation?
Yes. Waldencast voluntarily contacted the SEC about the issues, fully cooperated throughout the investigation, and dedicated significant resources to the process. The company states it incurred substantial legal, advisory and other related costs while maintaining focus on governance, controls and business execution.
How has Waldencast (WALD) described the outcome of the SEC investigation?
Waldencast’s CEO called the outcome favorable, noting SEC staff do not intend to recommend an enforcement action. The company emphasized its cooperation, focus on strong governance and robust internal controls, and continued execution of its business plans during the course of the investigation.
What is the connection between Waldencast (WALD) and Obagi Cosmeceuticals in this matter?
The investigation related to Waldencast’s restatement and internal control weaknesses tied to historical accounting practices used by Obagi Cosmeceuticals. Obagi Medical is described as an advanced skin care line with more than 35 years’ experience addressing issues like premature aging and photodamage.
Where can investors find more information about Waldencast (WALD) and its brands?
Investors can visit Waldencast’s investor relations website at https://ir.waldencast.com for company information. Additional details on its brands are available at www.obagi.com for Obagi Medical, and www.milkmakeup.com for Milk Makeup, which focuses on vegan, clean, cruelty-free products.